# Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

> **NCT00103974** · PHASE1 · COMPLETED · sponsor: **Bayhill Therapeutics** · enrollment: 30 (—)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BHT-3009-01

## Key facts

- **NCT ID:** NCT00103974
- **Lead sponsor:** Bayhill Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 30 (—)
- **Last updated:** 2008-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103974, "Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00103974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*